Individual Donor Risk Assessment and Blood Safety

Authors: Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife; Daniela Hermelin, MD, Chief Medical Officer at ImpactLife; Kip Kuttner, DO, Vice President and Medical Director at Miller-Keystone Blood Center; Richard Gammon, MD, Medical Director at OneBlood; Debra Smith, MD, PhD, Medical Director at Carter BloodCare; Courtney Hopkins, DO, Senior Medical Officer at Vitalant; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center; Jed Gorlin, MD, MBA, Chief Medical Officer at America’s Blood Centers.

The authors disclose no conflicts.
I. HISTORICAL CONTEXT FOR THE MSM DEFERRAL

The deferral of MSM from blood donation began before identification of HIV as the cause of AIDS. When transfusion transmission was recognized, epidemiologic studies in the developed world had demonstrated disproportionate risk associated with MSM. This led to the MSM deferral that, absent sensitive and specific in vitro testing, was effective in reducing the collection of potentially infectious donations. The discovery of HIV allowed development of diagnostic and donor screening tests that currently detect new infections within ≤10 days after exposure.

70% of incident infections in the US are still among the <5% of the male population who identify as MSM. This disproportion made MSM an operationally simple screening criterion in donor rooms. However, more sophisticated analysis of HIV infections over time demonstrates that self-identification as MSM functions as a proxy for other behaviors that include multiple recent sexual partners, recent new partners, and condomless anal sex. A long history of advocacy, starting in the LGBTQ+ community, expanding to the international blood community, major medical associations, and legislators recognizes that risk is associated with behaviors, not gender or sexual preference. This is the scientific basis for permitting MSM at minimal risk of infection to donate while also addressing these behavioral risks in the general population.

II. THE PROCESS OF REGULATORY CHANGE

The Center for Biologics Evaluation and Research (CBER), operating through its Office of Blood Research and Review (OBRR) at FDA, is responsible for regulating biological products for human use, including human blood and blood components. To ensure effective engagement with the regulated community and the public, CBER/OBRR utilizes advisory committees and workshops. The agency develops policies by incorporating input from experts, the public and the regulated industry, particularly professionals specializing in donor management, HIV and infectious diseases and transfusion medicine. These valuable resources have been utilized extensively over several years to address the matter of the MSM deferral.
III. BLOOD SAFETY

Blood collectors and regulators are dedicated to ensuring the utmost safety of blood products. Significant progress has been made in understanding and addressing TTIs leading to historically low levels of residual risk in the US. Improved testing techniques, particularly molecular assays, have played a crucial role in nearly eliminating the risk of HIV, HBV, and HCV, providing substantial safety margins as we consider revisions in donor screening policies. The test-negative window period when false negative screening can occur is now ≤10 days, making the FDA 3-month deferrals for targeted behaviors highly conservative.

UK, Australia, and Canada have seen no significant changes following subsequent incremental decreases in the MSM deferral8-11. TTIMS data reveals that residual risks of HIV, HCV, and HIV per million donations remained unchanged in the two non-overlapping 15-month periods after the 2015 deferral modification to one year4. Extensive literature provides substantial evidence of associations between general HIV incidence and factors such as new and/or multiple sex partners and anal sex, regardless of donor sexual orientation. In the context of blood donors, the ENGAGE study demonstrated strong predictive values for injection drug use, having more than two anal sex partners, and engaging in new anal sex partnerships12. These findings align with those from the UK FAIR review4. The ADVANCE study (a preprint at this writing), supported by FDA, the Office of the Assistant Secretary for Health and the blood community, has identified a specific subgroup of low-risk HIV-negative MSM who can be identified through the use of questions outlined in the new guidance13. The donor assessment outlined in the new guidance applies to all donors, regardless of sex or gender6.

The purpose of these questions is to identify donors who may be at risk for TTI by inquiring about new sex partners, multiple sex partners, and anal sex three months preceding donation without considering gender or sexual orientation. The Blood DROPS study aimed to assess the motivating factors and level of compliance with deferral. Out of 3,185 donors surveyed, only 2.6% donated blood after engaging in male-male sex13. This study, along with others, indicates a low level of non-compliance with eligibility criteria, which is taken into account when estimating the current residual risk14,15. Additional data from the ADVANCE study are forthcoming and will provide further insights.

It is important to note that the use of antiretroviral drugs in pre- and post-exposure prophylaxis (PrEP and PEP) can delay both molecular and serologic assay positivity resulting in false negative tests16. Donors who have taken these medications by mouth are deferred three months from their last dose, while those who have received the medication via injection are deferred for two years due to the prolonged persistence of parenteral prophylactic drugs.

IV. INDIVIDUAL RISK ASSESSMENT ALGORITHM

The guidance requires these actions to replace the current 3-month MSM deferral6.

1. Defer for 3 months from the most recent sexual contact, an individual who has had a new sexual partner in the past 3 months.
2. Defer for 3 months from the most recent sexual contact, an individual who has had more than one sexual partner in the past 3 months.
3. Defer for 3 months from the most recent injection, an individual who has received any medication by injection (oral) to prevent HIV infection (i.e., antiviral PrEP or PEP).
4. Defer for two years from the most recent injection, an individual who has received any medication by injection to prevent HIV infection (e.g., long-acting antiviral PrEP or PEP).

Questions concerning HIV diagnoses, therapeutic antiretrovirals, blood exposures, injection drug use, sexually transmitted bacterial infections and remunerated sex remain in the donor questionnaire. A deferred donor may be eligible to donate after the 3-month period provided they meet all other eligibility criteria.

WEIGHTED RESIDUAL RISK/DONATION FOR INFECTION IN ALL DONORS IN NON-OVERLAPPING POST-CHANGE 15-MONTH INTERVALS IN TTIMS4

<table>
<thead>
<tr>
<th></th>
<th>Pre-change to a one-year MSM deferral</th>
<th>Post-change interval 1</th>
<th>Post-change interval 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>1:1,151,127</td>
<td>1:1,337,943</td>
<td>1:1,606,972</td>
</tr>
<tr>
<td>HCV</td>
<td>1:2,019,521</td>
<td>1:1,387,247</td>
<td>1:1,980,534</td>
</tr>
<tr>
<td>HBV</td>
<td>1:1,162,271</td>
<td>1:1,022,267</td>
<td>1:989,841</td>
</tr>
</tbody>
</table>
V. CONTINUED
HEMOVIGILANCE

Continuous surveillance efforts are necessary to track and document the longer-term impact on rates of HIV and other infectious disease markers, ensuring that they remain at low levels. Using TIMMS and other available methods, FDA will maintain surveillance of the safety of the blood supply following implementation of individual risk-based donor eligibility questions.4,6 By leveraging this large data set, blood establishments can proactively identify potential risks and take necessary measures to minimize TTI risks. Furthermore, the blood supply will be continuously monitored to assess the impact of changes in donor eligibility criteria.

REFERENCES

9. Caffery N, Goldman M, Osmond L et al. HIV incidence and compliance with deferral criteria over three progressively shorter time deferrals for men who have sex with men in Canada. Transfusion 2022. 62;125-134
11. Seed CR, Kiely P, Law M, Keller AJ. No evidence of a significantly increased risk of transfusion transmitted immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have sex with men. Transfusion.2010. 50;2722-2730.

Blood Bulletin is issued periodically by America’s Blood Centers. Publication Editor: Mack Benton. The opinions expressed herein are opinions only and should not be construed as recommendations or standards of ABC. ABC SMT Committee, or its board of directors. Publication Office: 1717 K St. NW, Suite 900, Washington, DC 20006. Tel: (202) 393-5725; Fax: (202) 393-1282; E-mail: memberservices@americanblood.org. Copyright America’s Blood Centers, 2023 Reproduction is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)